Table 2.
Subgroup analysis of acetoacetate (per 10 µmoL/L increase) for all-cause death.
Factor | Subgroup | N | HR | 95%CI | P value | InteractionP value |
---|---|---|---|---|---|---|
Total | 615 | 1.020 | 1.010–1.030 | <0.001 | ||
Age | Age 67 years < | 245 | 0.932 | 0.784–1.104 | 0.402 | 0.284 |
Age 67 years ≥ | 370 | 1.020 | 1.010–1.020 | <0.001 | ||
Sex | Male | 374 | 1.010 | 1.001–1.020 | 0.004 | 0.005 |
Female | 241 | 1.051 | 1.030–1.083 | <0.001 | ||
NYHA classification | I, II | 362 | 1.041 | 1.041–1.051 | <0.001 | 0.001 |
III, IV | 253 | 1.010 | 0.990–1.020 | 0.335 | ||
Ischemic etiology | ± | 147 | 1.010 | 1.001–1.020 | 0.047 | 0.110 |
– | 468 | 1.030 | 1.010–1.040 | <0.001 | ||
Hypertension | ± | 395 | 1.010 | 1.001–1.030 | 0.011 | 0.094 |
– | 220 | 1.030 | 1.010–1.041 | <0.001 | ||
Diabetes mellitus | ± | 256 | 1.010 | 1.000–1.020 | 0.057 | 0.013 |
– | 359 | 1.041 | 1.020–1.051 | <0.001 | ||
Dyslipidemia | ± | 392 | 1.020 | 1.010–1.030 | <0.001 | 0.668 |
– | 223 | 1.010 | 0.990–1.041 | 0.305 | ||
Atrial fibrillation | ± | 249 | 1.030 | 1.010–1.051 | 0.015 | 0.479 |
– | 336 | 1.020 | 1.010–1.030 | <0.001 | ||
Chronic kidney disease | ± | 324 | 1.030 | 1.020–1.051 | <0.001 | 0.060 |
– | 291 | 1.010 | 1.000–1.030 | 0.026 | ||
Anemia | ± | 293 | 1.010 | 1.010–1.020 | <0.001 | 0.590 |
– | 322 | 1.020 | 1.000–1.051 | 0.094 | ||
Log BNP | Mean 2.3 ≥ | 340 | 1.010 | 1.001–1.020 | 0.042 | 0.007 |
Mean 2.3 < | 275 | 1.030 | 1.020–1.041 | <0.001 |
HR, hazard ratio; CI, confidence interval; NYHA, New York Heart Association; BNP, B-type natriuretic peptide.